Motor Peripheral Neuropathy

Categories: Neuronal diseases, Muscle diseases

Aliases & Classifications for Motor Peripheral Neuropathy

MalaCards integrated aliases for Motor Peripheral Neuropathy:

Name: Motor Peripheral Neuropathy 12 15
Peripheral Motor Neuropathy 12 73
Motor Neuritis 12 15
Hsmn - Hereditary Sensory and Motor Neuropathy 12
Neuropathy, Motor and Sensory, Hereditary 40
Hereditary Motor and Sensory Neuropathies 73
Hereditary Motor and Sensory Neuropathy 12
Hereditary Sensory and Motor Neuropathy 44
Neuropathic Muscular Atrophy 12
Hsmn 12


Summaries for Motor Peripheral Neuropathy

MalaCards based summary : Motor Peripheral Neuropathy, also known as peripheral motor neuropathy, is related to charcot-marie-tooth disease, axonal, type 2a1 and charcot-marie-tooth disease, x-linked dominant, 1, and has symptoms including neurologic symptoms An important gene associated with Motor Peripheral Neuropathy is PMP22 (Peripheral Myelin Protein 22), and among its related pathways/superpathways is Neural Crest Differentiation. The drugs Lidocaine and Donepezil have been mentioned in the context of this disorder. Affiliated tissues include kidney, testes and liver, and related phenotypes are behavior/neurological and cellular

Related Diseases for Motor Peripheral Neuropathy

Diseases related to Motor Peripheral Neuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 73)
# Related Disease Score Top Affiliating Genes
1 charcot-marie-tooth disease, axonal, type 2a1 33.0 KIF1B MFN2
2 charcot-marie-tooth disease, x-linked dominant, 1 32.9 GJB1 MPZ
3 roussy-levy hereditary areflexic dystasia 32.8 MPZ PMP22
4 charcot-marie-tooth disease, demyelinating, type 1c 32.5 KIF1B MPZ PMP22
5 charcot-marie-tooth disease, axonal, type 2b 32.2 GJB1 KIF1B MPZ PMP22
6 charcot-marie-tooth neuropathy type 1 31.8 GJB1 MPZ PMP22
7 hypertrophic neuropathy of dejerine-sottas 31.8 GJB1 KIF1B MPZ MTMR2 PMP22
8 charcot-marie-tooth disease type 2a 31.7 KIF1B MFN2
9 charcot-marie-tooth disease, demyelinating, type 1b 31.5 GJB1 KIF1B MPZ MTMR2 PMP22
10 charcot-marie-tooth disease, type 4d 31.5 GJB1 MFN2 NDRG1
11 neuropathy, hereditary, with liability to pressure palsies 30.5 GJB1 KIF1B MFN2 MPZ PMP22
12 hereditary motor and sensory neuropathy, type iic 30.5 GJB1 KIF1B MFN2 MPZ NDRG1 TFG
13 charcot-marie-tooth disease, demyelinating, type 1a 29.9 GJB1 KIF1B MFN2 MPZ MTMR2 PMP22
14 charcot-marie-tooth disease and deafness 29.8 GJB1 KIF1B MFN2 MPZ MTMR2 PMP22
15 charcot-marie-tooth disease, demyelinating, type 1d 29.6 GJB1 KIF1B MPZ MTMR2 NDRG1 PMP22
16 neuritis 29.1 MPZ PMP22
17 charcot-marie-tooth disease 28.6 GJB1 KIF1B MFN2 MPZ MTMR2 NDRG1
18 hereditary neuropathies 28.4 GJB1 MFN2 MPZ MTMR2 NDRG1 PMP22
19 peripheral nervous system disease 27.8 GJB1 MFN2 MPZ MTMR2 PMP22
20 charcot-marie-tooth disease, axonal, type 2e 27.6 GJB1 KIF1B MFN2 MPZ MTMR2 NDRG1
21 neuropathy 27.5 GJB1 MFN2 MPZ PMP22 SLC12A6 TFG
22 neuropathy, congenital hypomyelinating or amyelinating, autosomal recessive 27.4 DCAF8 GJB1 KIF1B MFN2 MPZ MTMR2
23 sensory peripheral neuropathy 27.4 GJB1 MFN2 MPZ MTMR2 NDRG1 PMP22
24 hereditary motor and sensory neuropathy v 12.7
25 hereditary motor and sensory neuropathy with acrodystrophy 12.4
26 gdap1-related hereditary motor and sensory neuropathy 12.2
27 neuropathy, hereditary motor and sensory, type via 12.2
28 neuropathy, hereditary motor and sensory, russe type 12.1
29 charcot-marie-tooth disease, axonal, autosomal dominant, type 2a2a 12.1
30 agenesis of the corpus callosum with peripheral neuropathy 12.1
31 neuropathy, hereditary motor and sensory, okinawa type 12.0
32 neuropathy, hereditary motor and sensory, type vib 11.7
33 refsum disease, classic 11.5
34 neuropathy, hereditary motor and sensory, with deafness, mental retardation, and absent sensory large myelinated fibers 11.5
35 giant axonal neuropathy 2, autosomal dominant 11.5
36 charcot-marie-tooth disease, axonal, type 2t 11.5
37 charcot-marie-tooth disease type 2a2 11.5
38 cowchock syndrome 11.4
39 charcot-marie-tooth disease, type 4b2 11.4
40 charcot-marie-tooth disease, axonal, type 2b1 11.4
41 charcot-marie-tooth disease, axonal, type 2b2 11.4
42 x-linked charcot-marie-tooth disease 11.4
43 neuropathy, hereditary sensory and autonomic, type iia 11.2
44 charcot-marie-tooth disease type 5 11.2
45 autosomal dominant charcot-marie-tooth disease type 2 with giant axons 11.2
46 charcot-marie-tooth disease type 2c 11.2
47 pmp2-related charcot-marie-tooth disease type 1 11.2
48 motor neuropathy, peripheral, with dysautonomia 11.1
49 intermittent claudication 11.1
50 motor sensory neuropathy type 1 aplasia cutis congenita 11.1

Graphical network of the top 20 diseases related to Motor Peripheral Neuropathy:

Diseases related to Motor Peripheral Neuropathy

Symptoms & Phenotypes for Motor Peripheral Neuropathy

UMLS symptoms related to Motor Peripheral Neuropathy:

neurologic symptoms

MGI Mouse Phenotypes related to Motor Peripheral Neuropathy:

# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.02 MPZ MTMR2 NDRG1 GJB1 PMP22 KIF1B
2 cellular MP:0005384 9.87 MFN2 TARDBP MPZ NDRG1 GJB1 PMP22
3 growth/size/body region MP:0005378 9.86 TARDBP MTMR2 NDRG1 GJB1 PMP22 KIF1B
4 mortality/aging MP:0010768 9.76 TARDBP MPZ MTMR2 NDRG1 GJB1 PMP22
5 muscle MP:0005369 9.43 TARDBP NDRG1 PMP22 KIF1B SLC12A6 MFN2
6 nervous system MP:0003631 9.28 MPZ MTMR2 NDRG1 GJB1 PMP22 KIF1B

Drugs & Therapeutics for Motor Peripheral Neuropathy

Drugs for Motor Peripheral Neuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 159)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Lidocaine Approved, Vet_approved Phase 4,Not Applicable 137-58-6 3676
Donepezil Approved Phase 4 120014-06-4 3152
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
Norepinephrine Approved Phase 4 51-41-2 439260
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3 59-30-3 6037
8 Analgesics Phase 4,Phase 3,Phase 2,Not Applicable
9 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
10 Antioxidants Phase 4,Phase 2,Phase 3
11 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1
12 Protective Agents Phase 4,Phase 2,Phase 3
13 Thioctic Acid Phase 4,Phase 2
14 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1
15 Vitamin B Complex Phase 4,Phase 2,Phase 3
16 Vitamins Phase 4,Phase 2,Phase 3,Phase 1
17 Anti-Anxiety Agents Phase 4,Phase 2
18 Anticonvulsants Phase 4,Phase 2
19 Antidepressive Agents Phase 4,Phase 3
20 calcium channel blockers Phase 4,Phase 2
21 Calcium, Dietary Phase 4,Phase 2
22 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
23 Cholinergic Agents Phase 4,Phase 2,Phase 3
24 Excitatory Amino Acid Antagonists Phase 4,Phase 3
25 Excitatory Amino Acids Phase 4,Phase 3
26 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
27 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3
28 Nootropic Agents Phase 4,Phase 2,Phase 3
29 Psychotropic Drugs Phase 4,Phase 3,Phase 2
30 Tranquilizing Agents Phase 4,Phase 3,Phase 2
31 Anesthetics Phase 4,Phase 3,Not Applicable
32 Anti-Arrhythmia Agents Phase 4,Phase 2
33 Anti-Inflammatory Agents Phase 4,Phase 2
34 Diuretics, Potassium Sparing Phase 4,Phase 2
35 Sodium Channel Blockers Phase 4,Phase 2
36 Hormone Antagonists Phase 4,Phase 2,Phase 3
37 Hormones Phase 4,Phase 2,Phase 3
38 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3
39 Immunosuppressive Agents Phase 4,Phase 2
40 Antimanic Agents Phase 4
41 Antiparkinson Agents Phase 4
42 Cholinesterase Inhibitors Phase 4
43 Dopamine Agents Phase 4
44 Duloxetine Hydrochloride Phase 4
45 GABA Agents Phase 4
46 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
47 Alpha-lipoic Acid Nutraceutical Phase 4,Phase 2
48 Folate Nutraceutical Phase 4,Phase 2,Phase 3
49 Vitamin B9 Nutraceutical Phase 4,Phase 2,Phase 3
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202

Interventional clinical trials:

(show top 50) (show all 103)
# Name Status NCT ID Phase Drugs
1 Postoperative Alpha Lipoic Acid in the Carpal Tunnel Syndrome: a Randomized Controlled Trial. Completed NCT01895621 Phase 4
2 Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy Terminated NCT00619983 Phase 4 donepezil;duloxetine;donepezil 2.5 mg and duloxetine 30mg;placebo;gabapentin
3 Lidocaine and Triamcinolone vs Saline Trigger Point Injection for Treatment of Chronic Abdominal Wall Pain Withdrawn NCT02748395 Phase 4 Triamcinolone;Lidocaine
4 Treadmill, Stretching and Proprioceptive Exercise (TreSPE) Rehabilitation Program for Charcot−Marie−Tooth Neuropathy Type 1A (CMT1A) Unknown status NCT01289704 Phase 2, Phase 3
5 Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Multifocal Motor Neuropathy. Completed NCT01827072 Phase 3 NPB-01
6 Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy Completed NCT00666263 Phase 3
7 LIME Study (LFB IVIg MMN Efficacy Study) Completed NCT01951924 Phase 3 Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL);Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)
8 Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer Completed NCT00369564 Phase 3 glutamic acid
9 Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer Completed NCT00516503 Phase 3 baclofen/amitriptyline/ketamine gel
10 High Dose Ascorbic Acid Treatment of CMT1A Completed NCT00484510 Phase 2, Phase 3 Ascorbic acid (Vitamin C);placebo
11 Acetyl-l-carnitine to Enhance Nerve Regeneration in Carpal Tunnel Syndrome Completed NCT02141035 Phase 2, Phase 3 Acetyl-l-carnitine;placebo
12 Effects of Botulinum Toxin Injections in Patients With Hereditary Spastic Paraplegia Completed NCT02604186 Phase 2, Phase 3
13 Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid Completed NCT00007020 Phase 3 Cholic Acids
14 Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Recruiting NCT03023540 Phase 3 PXT3003
15 Setmelanotide Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity Recruiting NCT03013543 Phase 2, Phase 3 Setmelanotide
16 Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT) Active, not recruiting NCT02579759 Phase 3 PXT3003 dose 1;PXT3003 dose 2;placebo
17 Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome Enrolling by invitation NCT03184584 Phase 2, Phase 3 PBI-4050
18 Erythropoietin Spinal Cord Compression Randomized Trial Terminated NCT00220675 Phase 2, Phase 3 Erythropoietin infusion
19 Subcutaneous Immunoglobulin Treatment for Multifocal Motor Neuropathy Completed NCT00268788 Phase 2 Subcutaneous immunoglobulin;Intravenous immunoglobulin
20 Efficacy and Safety of HyQvia (Immunoglobulin 10% With Recombinant Hyaluronidase) in Multifocal Motor Neuropathy (MMN) Completed NCT02556437 Phase 2 HyQvia;Subcuvia
21 A Study of Purified Human Antibodies Administered Subcutaneously to Patients With Multifocal Motor Neuropathy (MMN) Completed NCT00701662 Phase 2
22 Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy Completed NCT00041795 Phase 2 leteprinim potassium (Neotrofin)
23 Pregabalin in Preventing Acute Pain Syndrome in Patients Receiving Paclitaxel Completed NCT01637077 Phase 2 pregabalin;placebo
24 Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy Completed NCT00760955 Phase 2 TAK-583;TAK-583;TAK-583;Placebo
25 A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain Completed NCT01345045 Phase 2 ABT-639;pregabalin;Placebo
26 Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin Amyloidosis Completed NCT01171859 Phase 2 Doxycycline + Tauroursodeoxycholic acid
27 The Treatment of the Median Nerve for the Elimination of the Symptoms Associated With the Carpal Tunnel Syndrome Completed NCT00634738 Phase 1, Phase 2
28 Effects of Coenzyme Q10 on Charcot-Marie-Tooth Disease Completed NCT00541164 Phase 1, Phase 2 Coenzyme Q10
29 Ascorbic Acid Treatment in CMT1A Trial (AATIC) Completed NCT00271635 Phase 2 Placebo;ascorbic acid
30 Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A Completed NCT01401257 Phase 2 PXT3003 Low dose;PXT3003 Intermediate Dose;PXT3003 High Dose
31 Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease Completed NCT02561702 Phase 2 Mexiletine
32 Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer Completed NCT00983801 Phase 2 Ixabepilone
33 A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer Completed NCT00383149 Phase 2 Ixabepilone;Cetuximab
34 Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5 Completed NCT02314208 Phase 2 Xenbilox;Tahor
35 Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A Recruiting NCT03520751 Phase 1, Phase 2 scAAV1.tMCK.NTF3
36 Influence of Pronator Teres Release on Treatment of Median Nerve Compression Neuropathy Recruiting NCT01562860 Phase 2
37 Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Recruiting NCT03124459 Phase 2 ACE-083;Placebo
38 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Recruiting NCT02967679 Phase 1, Phase 2 MD1003
39 MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis Recruiting NCT02171104 Phase 2 IMD Preparative Regimen;Osteopetrosis Only Preparative Regimen;Osteopetrosis Haploidentical Only Preparative Regimen;cALD SR-A (Standard-Risk, Regimen A);cALD SR-B (Standard-Risk, Regimen B);cALD HR-D (High-Risk, Regimen C);cALD HR-D (High-Risk, Regimen D)
40 Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx Active, not recruiting NCT01088802 Phase 2 Cisplatin;Carboplatin
41 A Study to Assess the Safety and Effectiveness of FLX-787 in Subjects With Charcot-Marie-Tooth Disease Experiencing Muscle Cramps. Active, not recruiting NCT03254199 Phase 2 FLX-787-ODT (orally disintegrating tablet);Placebo ODT
42 Safety and Tolerability of PBI-4050 and Its Effects on the Biomarkers in Subjects With Alström Syndrome Active, not recruiting NCT02739217 Phase 2 PBI-4050
43 NB2013-HR German (GPOH) / Dutch (DCOG) Trial Terminated NCT02641782 Phase 2 antibody ch14.18;GM-CSF;IL-2 i.v.;IL-2 s.c.;Retinoic acid
44 Ulipristal Acetate In Disease Charcot-Marie-Tooth Type of 1A Terminated NCT02600286 Phase 2 EllaOne;EllaOne placebo
45 Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy Recruiting NCT02362438 Phase 1 Intrathecal Delivery of scAAV9/JeT-GAN
46 L-glutamine Supplementation to Alleviate Symptoms of Taxane-Induced Neuropathy in Patients With Breast Cancer Withdrawn NCT02215083 Phase 1
47 Change of Nerve Conduction Properties in IVIg Dependent Neuropathies Unknown status NCT01655394
48 A Study to Evaluate the Performance of a Diagnostic Test in ALS Unknown status NCT02759913
49 sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN Unknown status NCT02271724
50 Functional Electrical Stimulation in Chronic Kidney Disease Unknown status NCT02336776 Not Applicable

Search NIH Clinical Center for Motor Peripheral Neuropathy

Cochrane evidence based reviews: hereditary sensory and motor neuropathy

Genetic Tests for Motor Peripheral Neuropathy

Anatomical Context for Motor Peripheral Neuropathy

MalaCards organs/tissues related to Motor Peripheral Neuropathy:

Kidney, Testes, Liver, Spinal Cord, Colon

Publications for Motor Peripheral Neuropathy

Articles related to Motor Peripheral Neuropathy:

# Title Authors Year
Both Schwann cell and axonal defects cause motor peripheral neuropathy in Ebf2-/- mice. ( 21220016 )
Paraneoplastic encephalomyelitis/sensory motor peripheral neuropathy - an autopsy case study. ( 16012914 )
Dapsone-induced motor peripheral neuropathy in pemphigus foliaceus. ( 8565254 )
Sensory and motor peripheral neuropathy in olivopontocerebellar atrophy. ( 3014798 )
Hereditary motor peripheral neuropathy predominantly affecting the arms. ( 180264 )

Variations for Motor Peripheral Neuropathy

Expression for Motor Peripheral Neuropathy

Search GEO for disease gene expression data for Motor Peripheral Neuropathy.

Pathways for Motor Peripheral Neuropathy

Pathways related to Motor Peripheral Neuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.81 GJB1 MPZ PMP22

GO Terms for Motor Peripheral Neuropathy

Biological processes related to Motor Peripheral Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 myelination GO:0042552 8.96 MPZ PMP22
2 chemical synaptic transmission GO:0007268 8.8 MPZ PMP22 SLC12A6

Sources for Motor Peripheral Neuropathy

9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
70 SNOMED-CT via Orphanet
72 Tocris
74 UMLS via Orphanet
Loading form....